IL13 and asthma: The following studies demonstrated compromised epithelial barriers in conditions like asthma, atopic dermatitis (AD), and CRS, exposure to barrier‐toxic substances, and the effects of type 2 immune responses, particularly cytokines IL‐4 and IL‐13 [7, 8, 9, 10].